文献速递其他结缔组织病

肌炎前瞻性注册研究(PROMIS):I. 下一代测序识别 HLA-DQA1 为抗 MDA5 抗体阳性皮肌炎的新遗传风险因素

The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis.
PubMed 文献 · Ann Rheum Dis · 2025-04-17

研究纳入231例抗MDA5+皮肌炎患者、127例抗MDA5−皮肌炎患者、1468例非皮肌炎风湿病患者和1027名健康对照,另加51例抗MDA5+皮肌炎患者用于验证,采用全外显子测序识别HLA等位基因、氨基酸和单核苷酸多态性。发现HLA-DQA1*06:01和HLA-DQB1*06:09与抗MDA5+皮肌炎显著相关,HLA-DQA1*06:01在抗MDA5+皮肌炎中频率为20.4%,高于抗MDA5−皮肌炎的6.69%和非皮肌炎风湿病的5.93%。HLA-DQA1*06:01与急性快速进展性间质性肺病(P < .001)、乳酸脱氢酶升高(P = .026)和死亡(P = .049)相关。

要点

  • HLA-DQA1*06:01在抗MDA5+皮肌炎中频率20.4%,高于抗MDA5−皮肌炎6.69%和非皮肌炎风湿病5.93%。
  • HLA-DQA1*06:01与急性快速进展性间质性肺病(P < .001)、乳酸脱氢酶升高(P = .026)和死亡(P = .049)相关。
  • 最强关联氨基酸为HLA-DQα1:69(P = 3.27 × 10-11),ARHGAP22基因rs76208937提示性显著(P = 7.99 × 10-6)。

核心结论

  • HLA-DQA1*06:01是抗MDA5+皮肌炎新的遗传和预后因素,可能作为早期诊断和干预的生物标志物。

研究设计与样本

  • 前瞻性注册研究,纳入231例抗MDA5+皮肌炎患者、127例抗MDA5−皮肌炎患者、1468例非皮肌炎风湿病患者和1027名健康对照,另加51例抗MDA5+皮肌炎患者用于验证。
  • 采用全外显子测序识别主要组织相容性复合体(MHC)和非MHC区域的人类白细胞抗原(HLA)等位基因、氨基酸和单核苷酸多态性(SNPs),通过比较不同对照组进行关联研究,并开展临床关联研究。

主要发现

  • HLA-DQA1*06:01和HLA-DQB1*06:09在发现队列和验证队列中均与抗MDA5+皮肌炎显著相关。
  • HLA-DQA1*06:01在抗MDA5+皮肌炎中频率为20.4%,高于抗MDA5−皮肌炎的6.69%和非皮肌炎风湿病的5.93%。
  • 最强关联氨基酸为HLA-DQα1:69(P = 3.27 × 10-11),ARHGAP22基因rs76208937显示提示性显著(P = 7.99 × 10-6)。
  • 在抗MDA5+皮肌炎患者中,HLA-DQA1*06:01与急性快速进展性间质性肺病(P < .001)、乳酸脱氢酶水平升高(P = .026)和死亡(P = .049)相关。

临床怎么用

  • 作者认为HLA-DQA1*06:01可能作为抗MDA5+皮肌炎早期诊断和干预的生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Antimelanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare subtype of myositis with a poor prognosis and insufficient genetic understanding. Our study aimed to identify risk variants associated with anti-MDA5+ DM and to assess their correlation with clinical outcomes. METHODS: We enrolled 231 anti-MDA5+ DM patients, 127 anti-MDA5⁻ DM patients, 1468 patients with non-DM rheumatic disease, and 1027 healthy controls, with an additional 51 anti-MDA5+ DM patients for validation. Whole-exome sequencing was used to identify human leukocyte antigen (HLA) alleles, amino acids, and single nucleotide polymorphisms (SNPs) in major histocompatibility complex (MHC) and non-MHC regions. Association studies were performed to identify genetic variants associated with anti-MDA5+ DM by comparing different sets of control groups. A clinical association study was conducted to further explore the influence of genetic factors on clinical manifestations. RESULTS: Two novel genetic risks, HLA-DQA1*06:01 and HLA-DQB1*06:09, were significantly associated with anti-MDA5+ DM in both the discovery and validation cohorts. HLA-DQA1*06:01 was particularly prevalent in anti-MDA5+ DM (20.4%) compared with anti-MDA5⁻ DM (6.69%) and non-DM rheumatic disease (5.93%). Besides, the strongest associated amino acid was HLA-DQα1:69 (P = 3.27 × 10-11), and 1 SNP in the ARHGAP22 gene (rs76208937) showed suggestive significance (P = 7.99 × 10-6). In addition, HLA-DQA1*06:01 was linked to acute rapidly progressive interstitial lung disease (P < .001), elevated levels of lactate dehydrogenase (P = .026), and death (P = .049) in patients with anti-MDA5+ DM. CONCLUSIONS: HLA-DQA1*06:01 is a new genetic and prognostic factor for anti-MDA5+ DM, potentially serving as a biomarker for early diagnosis and intervention.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Yang X, Yu C, Zhang X, et al. The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis. Ann Rheum Dis. 2025. PMID: 40246682. doi:10.1016/j.ard.2025.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。